Tvardi Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 12

Employees

  • Stock Symbol
  • TVRD

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.99
  • (As of Friday Closing)

Tvardi Therapeutics General Information

Description

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 3 Sugar Creek Center Boulevard
  • Suite 525
  • Sugar Land, TX 77478
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 3 Sugar Creek Center Boulevard
  • Suite 525
  • Sugar Land, TX 77478
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tvardi Therapeutics Stock Performance

As of 20-Nov-2026, Tvardi Therapeutics’s stock price is $0.99. Its current market cap is $13.2M with 13.4M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.99 $0.93 $0.77 - $5.69 $13.2M 13.4M 235K -$2.63

Tvardi Therapeutics Financials Summary

As of 30-Sep-2026, Tvardi Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,054 4,108
Revenue 0 0 0 0
EBITDA (27,500) (19,494) (30,049) (18,570)
Net Income (26,660) (18,214) (29,397) (17,347)
Total Assets 23,533 32,073 35,199 27,001
Total Debt 116 201 30,563 368
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tvardi Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tvardi Therapeutics‘s full profile, request access.

Request a free trial

Tvardi Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Tvardi Therapeutics‘s full profile, request access.

Request a free trial

Tvardi Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molec
Drug Discovery
Sugar Land, TX
12 As of 2025

Wilmington, DE
 

Marseille, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tvardi Therapeutics Competitors (43)

One of Tvardi Therapeutics’s 43 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ayala Pharmaceuticals Corporation Wilmington, DE
Innate Pharma Formerly VC-backed Marseille, France
Gilead Formerly VC-backed Foster City, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
You’re viewing 5 of 43 competitors. Get the full list »

Tvardi Therapeutics Patents

Tvardi Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025184497-A1 Stat3 inhibitors for use in the treatment of cancer Pending 29-Feb-2024
WO-2025137366-A2 Solid-state forms of stat3 inhibitors and methods of use thereof Inactive 20-Dec-2023
WO-2025137366-A3 Solid-state forms of stat3 inhibitors and methods of use thereof Inactive 20-Dec-2023
WO-2025054280-A1 Formulations of stat3 inhibitors and methods of use thereof Inactive 05-Sep-2023
WO-2024129619-A1 Stat3 inhibitors for use in the treatment of non-viral liver cancer Inactive 12-Dec-2022 A61K31/18
To view Tvardi Therapeutics’s complete patent history, request access »

Tvardi Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tvardi Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Tvardi Therapeutics‘s full profile, request access.

Request a free trial

Tvardi Therapeutics Acquisitions (1)

Tvardi Therapeutics’s most recent deal was a Merger/Acquisition with Cara Therapeutics. The deal was made on 15-Apr-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cara Therapeutics 15-Apr-2025 Merger/Acquisition Drug Discovery
To view Tvardi Therapeutics’s complete acquisitions history, request access »

Tvardi Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Tvardi Therapeutics’s complete esg history, request access »

Tvardi Therapeutics FAQs

  • When was Tvardi Therapeutics founded?

    Tvardi Therapeutics was founded in 2017.

  • Where is Tvardi Therapeutics headquartered?

    Tvardi Therapeutics is headquartered in Sugar Land, TX.

  • What is the size of Tvardi Therapeutics?

    Tvardi Therapeutics has 12 total employees.

  • What industry is Tvardi Therapeutics in?

    Tvardi Therapeutics’s primary industry is Drug Discovery.

  • Is Tvardi Therapeutics a private or public company?

    Tvardi Therapeutics is a Public company.

  • What is Tvardi Therapeutics’s stock symbol?

    The ticker symbol for Tvardi Therapeutics is TVRD.

  • What is the current stock price of Tvardi Therapeutics?

    As of 20-Nov-2026 the stock price of Tvardi Therapeutics is $0.99.

  • What is the current market cap of Tvardi Therapeutics?

    The current market capitalization of Tvardi Therapeutics is $13.2M.

  • Who are Tvardi Therapeutics’s competitors?

    Ayala Pharmaceuticals, Innate Pharma, Gilead, Kite Pharma, and Marengo Therapeutics are some of the 43 competitors of Tvardi Therapeutics.

  • What is Tvardi Therapeutics’s annual earnings per share (EPS)?

    Tvardi Therapeutics’s EPS for 12 months was -$2.63.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process